| Revision as of 16:17, 29 July 2010 editPotatoBot (talk | contribs)Bots51,239 editsm Stub sorting and placement of stub template(s)← Previous edit |
Latest revision as of 11:47, 22 June 2024 edit undoVaccinationist (talk | contribs)Extended confirmed users4,733 edits Skeletal formulaTag: 2017 wikitext editor |
| (37 intermediate revisions by 26 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
| ⚫ |
| IUPAC_name = |
|
|
|
| Watchedfields = changed |
|
| image = |
|
|
|
| verifiedrevid = 444399735 |
| ⚫ |
| CAS_number = |
|
|
⚫ |
| IUPAC_name = |
| ⚫ |
| ATC_prefix = L01 |
|
|
|
| image = Oblimersen.svg |
| ⚫ |
| ATC_suffix = XX36 |
|
|
|
| width = 300 |
|
| PubChem = |
|
|
|
|
| ⚫ |
| DrugBank = |
|
|
|
<!--Clinical data--> |
|
| chemical_formula = |
|
|
|
| tradename = Genasense |
| ⚫ |
| molecular_weight = |
|
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| ⚫ |
| bioavailability = |
|
|
|
| pregnancy_US = <!-- A / B / C / D / X --> |
| ⚫ |
| protein_bound = |
|
|
⚫ |
| pregnancy_category = |
| ⚫ |
| metabolism = |
|
|
⚫ |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| ⚫ |
| elimination_half-life = |
|
|
⚫ |
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
| ⚫ |
| excretion = |
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
⚫ |
| legal_status = Not marketed |
| ⚫ |
| pregnancy_category= |
|
|
⚫ |
| routes_of_administration = |
| ⚫ |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
|
|
|
| ⚫ |
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
|
|
<!--Pharmacokinetic data--> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
|
⚫ |
| bioavailability = |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
|
⚫ |
| protein_bound = |
| ⚫ |
| legal_status = |
|
|
⚫ |
| metabolism = |
| ⚫ |
| routes_of_administration = |
|
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
| ChemSpiderID = 34980574 |
|
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
⚫ |
| CAS_number = 190977-41-4 |
|
⚫ |
| ATC_prefix = L01 |
|
⚫ |
| ATC_suffix = XX36 |
|
|
| PubChem = Oblimersen |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 85J5ZP6YSL |
|
|
| synonyms = G3139 |
|
|
|
|
|
<!--Chemical data--> |
|
|
| C=172 | H=221 | N=62 | O=91 | P=17 | S=17 |
|
⚫ |
| molecular_weight = |
|
|
| smiles = Cc1cn(c(=O)c1=O)2C((O2)COP(=O)(O3C(O3COP(=O)(O4C(O4COP(=O)(O5C(O5COP(=O)(O6C(O6COP(=O)(O7C(O7COP(=O)(O8C(O8COP(=O)(O9C(O9COP(=O)(O1C(O1COP(=O)(O1C(O1COP(=O)(O1C(O1COP(=O)(O1C(O1COP(=O)(O1C(O1COP(=O)(O1C(O1COP(=O)(O1C(O1COP(=O)(O1C(O1COP(=O)(O1C(O1COP(=O)(O1C(O1CO)n1cc(c(=O)c1=O)C)S)n1ccc(nc1=O)N)S)n1cc(c(=O)c1=O)C)S)n1ccc(nc1=O)N)S)n1ccc(nc1=O)N)S)n1ccc(nc1=O)N)S)n1cnc2c1ncnc2N)S)n1cnc2c1nc(c2=O)N)S)n1ccc(nc1=O)N)S)n1cnc2c1nc(c2=O)N)S)n1cc(c(=O)c1=O)C)S)n1cnc2c1nc(c2=O)N)S)n1ccc(nc1=O)N)S)n1cnc2c1nc(c2=O)N)S)n1ccc(nc1=O)N)S)n1ccc(nc1=O)N)S)n1cnc2c1ncnc2N)S)O |
|
|
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChI = 1S/C172H221N62O91P17S17/c1-69-39-225(169(253)213-149(69)237)117-21-73(236)92(292-117)44-274-326(257,343)320-85-33-129(229-63-191-135-141(181)187-61-189-143(135)229)303-103(85)55-285-332(263,349)314-79-27-122(221-17-9-113(177)201-165(221)249)295-95(79)47-278-330(261,347)312-78-26-121(220-16-8-112(176)200-164(220)248)298-98(78)50-280-338(269,355)322-87-35-131(231-65-193-137-145(231)205-157(183)209-153(137)241)305-105(87)57-287-334(265,351)316-81-29-124(223-19-11-115(179)203-167(223)251)299-99(81)51-281-339(270,356)323-88-36-132(232-66-194-138-146(232)206-158(184)210-154(138)242)307-107(88)59-289-337(268,354)319-84-32-128(228-42-72(4)152(240)216-172(228)256)302-102(84)54-284-341(272,358)325-90-38-134(234-68-196-140-148(234)208-160(186)212-156(140)244)306-106(90)58-288-335(266,352)317-82-30-125(224-20-12-116(180)204-168(224)252)300-100(82)52-282-340(271,357)324-89-37-133(233-67-195-139-147(233)207-159(185)211-155(139)243)308-108(89)60-290-342(273,359)321-86-34-130(230-64-192-136-142(182)188-62-190-144(136)230)304-104(86)56-286-333(264,350)315-80-28-123(222-18-10-114(178)202-166(222)250)296-96(80)48-277-328(259,345)310-76-24-119(218-14-6-110(174)198-162(218)246)294-94(76)46-276-329(260,346)311-77-25-120(219-15-7-111(175)199-163(219)247)297-97(77)49-279-336(267,353)318-83-31-127(227-41-71(3)151(239)215-171(227)255)301-101(83)53-283-331(262,348)313-75-23-118(217-13-5-109(173)197-161(217)245)293-93(75)45-275-327(258,344)309-74-22-126(291-91(74)43-235)226-40-70(2)150(238)214-170(226)254/h5-20,39-42,61-68,73-108,117-134,235-236H,21-38,43-60H2,1-4H3,(H,257,343)(H,258,344)(H,259,345)(H,260,346)(H,261,347)(H,262,348)(H,263,349)(H,264,350)(H,265,351)(H,266,352)(H,267,353)(H,268,354)(H,269,355)(H,270,356)(H,271,357)(H,272,358)(H,273,359)(H2,173,197,245)(H2,174,198,246)(H2,175,199,247)(H2,176,200,248)(H2,177,201,249)(H2,178,202,250)(H2,179,203,251)(H2,180,204,252)(H2,181,187,189)(H2,182,188,190)(H,213,237,253)(H,214,238,254)(H,215,239,255)(H,216,240,256)(H3,183,205,209,241)(H3,184,206,210,242)(H3,185,207,211,243)(H3,186,208,212,244)/t73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,326?,327?,328?,329?,330?,331?,332?,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?/m0/s1 |
|
|
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChIKey = MIMNFCVQODTQDP-NDLVEFNKSA-N |
|
}} |
|
}} |
|
|
|
|
'''Oblimersen''' (], trade name '''Genasense'''; also known as '''Augmerosen''' and '''bcl-2 antisense oligodeoxynucleotide G3139''') is an ] ] being studied as a possible treatment for several types of ], including ], ], and ]. It may kill cancer cells by blocking the production of ]—a ] that makes cancer cells live longer—and by making them more sensitive to chemotherapy. |
|
'''Oblimersen''' (], trade name '''Genasense'''; also known as '''Augmerosen''' and '''bcl-2 antisense oligodeoxynucleotide G3139''') is an ] ] being studied as a possible treatment for several types of ], including ], ], and ]. It may kill cancer cells by blocking the production of ]—a ] that makes cancer cells live longer—and by making them more sensitive to chemotherapy. |
|
|
|
|
|
|
==History== |
| ⚫ |
== External links == |
|
|
|
The antisense ] drug oblimersen was developed by ] to target Bcl-2. An antisense DNA or RNA strand is non-coding and complementary to the coding strand (which is the template for producing respectively RNA or protein). An antisense drug is a short sequence of RNA which hybridises with and inactivates mRNA, preventing the protein from being formed.{{cn|date=February 2023}} |
| ⚫ |
* entry in the public domain NCI Dictionary of Cancer Terms |
|
|
|
|
|
|
|
It was shown that the proliferation of human ] ] (with t(14;18) translocation) could be inhibited by antisense RNA targeted at the start ] region of Bcl-2 ]. ] studies led to the identification of oblimersen, which is complementary to the first 6 codons of Bcl-2 mRNA.<ref name="pmid12445555">{{cite journal | vauthors = Dias N, Stein CA | title = Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides | journal = European Journal of Pharmaceutics and Biopharmaceutics | volume = 54 | issue = 3 | pages = 263–9 | date = November 2002 | pmid = 12445555 | doi = 10.1016/S0939-6411(02)00060-7 }}</ref> |
| ⚫ |
{{Chemotherapeutic agents}} |
|
|
|
|
|
|
|
These have shown successful results in Phase I/II trials for lymphoma, and a large Phase III trial was launched in 2004.<ref name="pmid15010151">{{cite journal | vauthors = Mavromatis BH, Cheson BD | title = Novel therapies for chronic lymphocytic leukemia | journal = Blood Reviews | volume = 18 | issue = 2 | pages = 137–48 | date = June 2004 | pmid = 15010151 | doi = 10.1016/S0268-960X(03)00039-0 }}</ref> |
|
|
|
|
|
|
By the first quarter 2010, the drug had not received ] approval due to disappointing results in a melanoma trial. Although its safety and efficacy have not been established for any use, Genta Incorporated still{{When|date=August 2021}} claims on its website that studies are currently under way to examine the potential role of oblimersen in a variety of clinical indications. |
| ⚫ |
] |
|
|
|
|
|
|
|
Recent studies in 2023 continue to explore the potential of oblimersen in combination with other therapies. Preclinical models have demonstrated that oblimersen, when combined with vinorelbine, significantly inhibits tumor growth and prolongs survival in NSCLC. These findings suggest that combining oblimersen with other chemotherapeutic agents could enhance its efficacy and potentially overcome previous clinical challenges. |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
⚫ |
== External links == |
|
⚫ |
* entry in the public domain NCI Dictionary of Cancer Terms |
|
|
|
|
⚫ |
{{Chemotherapeutic agents}} |
|
|
|
|
|
⚫ |
] |
|
{{antineoplastic-drug-stub}} |
|
|
|
] |
|
|
] |